secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2026-10-14T01:49:11+00:00
Accession:  0001104659-26-115672
Event type: litigation
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 1.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Liquidia to pay $380.7M to United Therapeutics, resolving all litigation and keeping YUTREPIA in PAH
--------------------------------------------------------------------------------

- Settlement resolves all six lawsuits with UTHR, including U.S. Patent 11,826,327, trade secret and antitrust cases; Liquidia will not appeal Delaware ruling.
- Liquidia will pay UTHR net $175.0M within 30 business days plus $145.4M in two $72.7M installments due Jan 31 and Apr 30, 2027.
- Liquidia will remove PH-ILD indication from YUTREPIA label and cease promotion; YUTREPIA remains marketed for PAH.
- Q3 2026 preliminary YUTREPIA net sales were $222.7M; cash and equivalents were $396.1M as of Sept 30, 2026.
- Liquidia also pays $60.3M to Sandoz, Henderson and PBM to settle RareGen antitrust interests; HCR minimum cash covenant rises to $45.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926115672/0001104659-26-115672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926115672/tm2627557d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-115672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer